# Adipose Derived Regenerative Cells In the Treatment of Diabetic Foot Ulcers

> **NCT05095389** · PHASE3 · UNKNOWN · sponsor: **Paracrine, INC.** · enrollment: 290 (estimated)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DEVICE:** ADRCs
- **OTHER:** standard care
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05095389
- **Lead sponsor:** Paracrine, INC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-28
- **Primary completion:** 2024-12
- **Final completion:** 2025-07
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05095389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05095389, "Adipose Derived Regenerative Cells In the Treatment of Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05095389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*